Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).

Orbai AM, Ogdie A, Gossec L, Tillett W, Leung YY, Gao J, Trivedi M, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Coates LC.

Rheumatology (Oxford). 2019 Oct 18. pii: kez408. doi: 10.1093/rheumatology/kez408. [Epub ahead of print]

PMID:
31624837
2.

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T.

JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055.

PMID:
31334793
3.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, Abi-Saab W, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Mozaffarian N, Liu K, Greer JM, Deodhar A, Landewé R.

Lancet. 2018 Dec 1;392(10162):2378-2387. doi: 10.1016/S0140-6736(18)32463-2. Epub 2018 Oct 22.

4.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, Abi-Saab W, Tasset C, Meuleners L, Harrison P, Besuyen R, Van der Aa A, Mozaffarian N, Greer JM, Kunder R, Van den Bosch F, Gladman DD.

Lancet. 2018 Dec 1;392(10162):2367-2377. doi: 10.1016/S0140-6736(18)32483-8. Epub 2018 Oct 22.

5.

Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.

Namour F, Fagard L, Van der Aa A, Harrison P, Xin Y, Tasset C.

Br J Clin Pharmacol. 2018 Dec;84(12):2779-2789. doi: 10.1111/bcp.13726. Epub 2018 Oct 4.

6.

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.

Genovese M, Westhovens R, Meuleners L, Van der Aa A, Harrison P, Tasset C, Kavanaugh A.

Arthritis Res Ther. 2018 Mar 23;20(1):57. doi: 10.1186/s13075-018-1541-z.

7.

POWERDRESS-mediated histone deacetylation is essential for thermomorphogenesis in Arabidopsis thaliana.

Tasset C, Singh Yadav A, Sureshkumar S, Singh R, van der Woude L, Nekrasov M, Tremethick D, van Zanten M, Balasubramanian S.

PLoS Genet. 2018 Mar 16;14(3):e1007280. doi: 10.1371/journal.pgen.1007280. eCollection 2018 Mar.

8.

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).

Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P.

Ann Rheum Dis. 2017 Jun;76(6):998-1008. doi: 10.1136/annrheumdis-2016-210104. Epub 2016 Dec 19.

9.

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).

Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P.

Ann Rheum Dis. 2017 Jun;76(6):1009-1019. doi: 10.1136/annrheumdis-2016-210105. Epub 2016 Dec 19.

10.

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis A, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, Harrison P.

Lancet. 2017 Jan 21;389(10066):266-275. doi: 10.1016/S0140-6736(16)32537-5. Epub 2016 Dec 15.

PMID:
27988142
11.

Nonsense-mediated mRNA decay modulates FLM-dependent thermosensory flowering response in Arabidopsis.

Sureshkumar S, Dent C, Seleznev A, Tasset C, Balasubramanian S.

Nat Plants. 2016 Apr 29;2(5):16055. doi: 10.1038/nplants.2016.55.

PMID:
27243649
12.

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.

Namour F, Desrivot J, Van der Aa A, Harrison P, Tasset C, van't Klooster G.

Drug Metab Lett. 2016;10(1):38-48.

PMID:
26693854
13.

Genetic Architecture of Natural Variation in Thermal Responses of Arabidopsis.

Sanchez-Bermejo E, Zhu W, Tasset C, Eimer H, Sureshkumar S, Singh R, Sundaramoorthi V, Colling L, Balasubramanian S.

Plant Physiol. 2015 Sep;169(1):647-59. doi: 10.1104/pp.15.00942. Epub 2015 Jul 20.

14.

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.

Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, Van't Klooster G.

Clin Pharmacokinet. 2015 Aug;54(8):859-74. doi: 10.1007/s40262-015-0240-z.

15.

[Prevalence, severity, and predictors of bronchopulmonary dysplasia in a cohort of very preterm infants].

Richard M, Ramful D, Robillard PY, Mussard C, Loumouamou Y, Ogier M, Tasset C, N'guyen AD, Alessandri JL, Sampériz S, Gérardin P.

Arch Pediatr. 2013 Sep;20(9):928-37. doi: 10.1016/j.arcped.2013.05.002. Epub 2013 Jul 2. French.

PMID:
23829969
16.

[Brain tuberculoma in a 10-year-old child: the diagnosis is in the belly].

Vernaz A, Enaud L, Blanc S, Stoven C, Tasset C, Losi S, Andriolo E, Piyaraly S, Flodrops H.

Arch Pediatr. 2012 Aug;19(8):832-6. doi: 10.1016/j.arcped.2012.05.014. Epub 2012 Jul 15. French.

PMID:
22796287
17.

Biological control of bacterial wilt in Arabidopsis thaliana involves abscissic acid signalling.

Feng DX, Tasset C, Hanemian M, Barlet X, Hu J, Trémousaygue D, Deslandes L, Marco Y.

New Phytol. 2012 Jun;194(4):1035-45. doi: 10.1111/j.1469-8137.2012.04113.x. Epub 2012 Mar 20.

18.

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.

Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P.

Br J Dermatol. 2012 Jul;167(1):180-90. doi: 10.1111/j.1365-2133.2012.10941.x. Epub 2012 Jun 11.

PMID:
22413944
19.

Arabidopsis EDS1 connects pathogen effector recognition to cell compartment-specific immune responses.

Heidrich K, Wirthmueller L, Tasset C, Pouzet C, Deslandes L, Parker JE.

Science. 2011 Dec 9;334(6061):1401-4. doi: 10.1126/science.1211641.

20.

Autoacetylation of the Ralstonia solanacearum effector PopP2 targets a lysine residue essential for RRS1-R-mediated immunity in Arabidopsis.

Tasset C, Bernoux M, Jauneau A, Pouzet C, Brière C, Kieffer-Jacquinod S, Rivas S, Marco Y, Deslandes L.

PLoS Pathog. 2010 Nov 18;6(11):e1001202. doi: 10.1371/journal.ppat.1001202.

21.

Acute chikungunya virus infection and asthma.

Paganin F, Tasset C, Poubeau P, Cochet V, Borgherini G.

Eur Respir J. 2010 Jun;35(6):1407-9. doi: 10.1183/09031936.00172909. No abstract available.

22.
23.

Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child.

Oranje AP, Stalder JF, Taïeb A, Tasset C, de Longueville M.

Pediatr Allergy Immunol. 1997 Feb;8(1):28-34.

PMID:
9260216
24.

[Clinical formulations of amphotericin B].

Tasset C, Preat V, Roland M.

J Pharm Belg. 1992 Nov-Dec;47(6):523-36. French.

PMID:
1289493
25.

Comparison of nephrotoxicities of different polyoxyethyleneglycol formulations of amphotericin B in rats.

Tasset C, Preat V, Bernard A, Roland M.

Antimicrob Agents Chemother. 1992 Jul;36(7):1525-31.

26.

The influence of Myrj 59 on the solubility, toxicity and activity of amphotericin B.

Tasset C, Préat V, Roland M.

J Pharm Pharmacol. 1991 May;43(5):297-302.

PMID:
1680169

Supplemental Content

Loading ...
Support Center